Tilray Brands stock trades at 2.36 euros as restructuring advances
Published on 11/12/2026 at 13:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSTilray advances operational restructuring
- Tilray plans to consolidate Canadian cultivation and pre-roll production to reduce costs and improve capacity use.
- The company raised the lower end of its fiscal 2027 adjusted EBITDA outlook to 70 million US dollars.
- Operations at the Foss facility are expected to conclude by January 31, 2027.
Tilray Brands stock traded at 2.36 euros on Lang & Schwarz at 13:49 CET on Thursday, November 12, 2026. The company is implementing a Canadian cannabis restructuring plan announced on November 2 that is intended to lower costs and improve operating efficiency.
Canadian facilities move into focus
According to Tilray Brands, cultivation will move from the Foss facility in Fenwick, Ontario, to Masson, Quebec, while pre-roll production will be consolidated at Cayuga, Ontario. Foss operations are expected to conclude by January 31, 2027, after current cultivation and harvest cycles are completed.
Tilray expects the initiative to generate approximately 10 million US dollars in annualized savings by the end of fiscal 2028. The company said Masson's annual cultivation capacity could rise from approximately 32.5 to 50 metric tonnes through higher yields and operational improvements.
Guidance floor moves higher
Tilray raised the lower end of its fiscal 2027 adjusted EBITDA guidance to 70 million US dollars from 68 million US dollars, while keeping the upper end at 75 million US dollars. The company said the revised outlook reflects operational efficiency measures and other cost-reduction initiatives.
The plan also includes a possible reestablishment of EU-GMP certification at Masson in calendar 2027, which could support international medical cannabis markets. Tilray said it expects uninterrupted product supply during the transition and plans to maintain the capacity needed for Canadian and international demand.
Tilray Brands stock at a glance
- Company: Tilray Brands, Inc.
- ISIN: US88688T2096
- Ticker: TLRY
- Home exchange: Nasdaq
- Lang & Schwarz quote: 2.36 euros at 13:49 CET on November 12, 2026
- Fiscal 2027 adjusted EBITDA outlook: 70 million to 75 million US dollars
Tilray's restructuring gives investors a clearer view of the company's effort to improve profitability while cannabis demand and regulatory conditions remain key variables. The planned savings are forward-looking targets, so execution at the consolidated facilities will determine their contribution to future earnings.
US equities, including Tilray Brands stock, are tracked alongside the S&P 500 market environment.
